Read on Twitter
$AKER -- Serial
Here, then, is PTI's Akers Biosciences serial -- but before we continue, please note:
$AKER is a very speculative opportunity -- to my eye, there are valid questions as to corporate management, and track record is not strong.
Nevertheless, value & science..
Here, then, is PTI's Akers Biosciences serial -- but before we continue, please note:
$AKER is a very speculative opportunity -- to my eye, there are valid questions as to corporate management, and track record is not strong.
Nevertheless, value & science..
$AKER
#COVID19 has been & will continue to be a worldwide scourge. My thoughts & prayers to those who have been affected directly, and indirectly.
And as difficult as this may be, nothing really changes -- with the shutdowns/closures, with the uncertainty, until:
vaccineS..
#COVID19 has been & will continue to be a worldwide scourge. My thoughts & prayers to those who have been affected directly, and indirectly.
And as difficult as this may be, nothing really changes -- with the shutdowns/closures, with the uncertainty, until:
vaccineS..
$AKER
Yes, vaccineS, very clearly plural -- FDA currently guides for approval of any candidate that evinces by RCT 50% efficacy or better...
The idea manifold, but here are 2:
- Sheer volume -- the whole world needs effective doses...
- what works for 1 may not another...
Yes, vaccineS, very clearly plural -- FDA currently guides for approval of any candidate that evinces by RCT 50% efficacy or better...
The idea manifold, but here are 2:
- Sheer volume -- the whole world needs effective doses...
- what works for 1 may not another...
$AKER
Stage set for a 'David'-like Akers among a field of biopharma Goliaths.
Any player that can develop an efficacious vaccine will have clear opportunity -- to contribute to the great need, to be rewarded for its efforts...
& some vaccines interesting in own right, no less
Stage set for a 'David'-like Akers among a field of biopharma Goliaths.
Any player that can develop an efficacious vaccine will have clear opportunity -- to contribute to the great need, to be rewarded for its efforts...
& some vaccines interesting in own right, no less
$AKER
Akers finds its way to this interesting candidate via p'ship with Indian company Premas Biotech -- and vaccines are old hat to Premas...
Not just any vaccines -- vaccines comprising Virus Like Particles (VLPs) derived from a mod. strain of yeast: https://pubmed.ncbi.nlm.nih.gov/20923267/
Akers finds its way to this interesting candidate via p'ship with Indian company Premas Biotech -- and vaccines are old hat to Premas...
Not just any vaccines -- vaccines comprising Virus Like Particles (VLPs) derived from a mod. strain of yeast: https://pubmed.ncbi.nlm.nih.gov/20923267/
$AKER
What's so interesting about VLPs is that, by dint of their form/composition, they MAY hold certain advantages to other vaccine modalities:
Any vaccine's first mandate is safety. Closely behind, of course is efficacy.
But this interplay is particularly constrained:
What's so interesting about VLPs is that, by dint of their form/composition, they MAY hold certain advantages to other vaccine modalities:
Any vaccine's first mandate is safety. Closely behind, of course is efficacy.
But this interplay is particularly constrained:
$AKER
Because all prophylactic vaccines are designed to 'spur' the endogenous immune system into action by presenting it with some 'form' of the very virus itself --
whether that's an attenuated form, an inactivated form, or in some cases, just a "part" of the virus.
The idea:
Because all prophylactic vaccines are designed to 'spur' the endogenous immune system into action by presenting it with some 'form' of the very virus itself --
whether that's an attenuated form, an inactivated form, or in some cases, just a "part" of the virus.
The idea:
$AKER
When presented w/ this "virus-like" thing, our immune system "reacts" as if it were the real thing by responding with the troops:
- creating neutralizing antibodies
- training T-cells to play offense
But sometimes, problem is this very 'immunogenicity' can be harmful..
When presented w/ this "virus-like" thing, our immune system "reacts" as if it were the real thing by responding with the troops:
- creating neutralizing antibodies
- training T-cells to play offense
But sometimes, problem is this very 'immunogenicity' can be harmful..
$AKER
Our immune system reacts to the 'fake' virus, and in the process of mounting that response, there can be side effects like fever, etc. And, sometimes, there can even be an "over" reaction to the stimulus.
So, we are left with the following:
Our immune system reacts to the 'fake' virus, and in the process of mounting that response, there can be side effects like fever, etc. And, sometimes, there can even be an "over" reaction to the stimulus.
So, we are left with the following:
$AKER
We want to present our bodies w/ a replica of the virus which is as close to the real thing as possible so that immune system can mount a comprehensive response,
but, if that replica is 'too close' to the real thing, there can be side effects, incl., rarely, infection.
We want to present our bodies w/ a replica of the virus which is as close to the real thing as possible so that immune system can mount a comprehensive response,
but, if that replica is 'too close' to the real thing, there can be side effects, incl., rarely, infection.
$AKER
This is precisely where Premas' VLP vaccine model may shine:
The 'L' in VLP is impt - this is not a virus, attenuated/inactivated or otherwise. Their VLP is modified baker's yeast, thus safer than the "real thing".
But, it also expresses multiple surface targets:
This is precisely where Premas' VLP vaccine model may shine:
The 'L' in VLP is impt - this is not a virus, attenuated/inactivated or otherwise. Their VLP is modified baker's yeast, thus safer than the "real thing".
But, it also expresses multiple surface targets:
$AKER
An orthogonal example of why a vaccine candidates' comprehensive presentation of viral antigens may be so important to efficacy--
Take a look at this recent study
An orthogonal example of why a vaccine candidates' comprehensive presentation of viral antigens may be so important to efficacy--
Take a look at this recent study
$AKER
Though the study relates to antibody therapies, note that these unique antibodies were produced/discovered in actual COVID-19 patients who went on to fully recover from the disease -- but a potential takeaway -- the mAbs that patients' immune systems produced...
Though the study relates to antibody therapies, note that these unique antibodies were produced/discovered in actual COVID-19 patients who went on to fully recover from the disease -- but a potential takeaway -- the mAbs that patients' immune systems produced...
$AKER
may have been proportional to the severity of the manifestation of the underlying disease for said patient.
The closer to the 'real thing' that vaccine can present, likely the more fully the vaccine recipient's body can respond w/ diverse, protective mAbs:
may have been proportional to the severity of the manifestation of the underlying disease for said patient.
The closer to the 'real thing' that vaccine can present, likely the more fully the vaccine recipient's body can respond w/ diverse, protective mAbs:
$AKER
And now to the elements that may make the AKER/Premas vaccine development situation even more favorable:
- highly scaleable (cheaper)
- potentially expedited developmental timeline w/ FDA, & concurrent regulatory discussions in Premas' native India:
And now to the elements that may make the AKER/Premas vaccine development situation even more favorable:
- highly scaleable (cheaper)
- potentially expedited developmental timeline w/ FDA, & concurrent regulatory discussions in Premas' native India:
$AKER /fin
And the next catalyst?
How about some animal study results -- 6 weeks from the PR would be mid-August...
And the next catalyst?
How about some animal study results -- 6 weeks from the PR would be mid-August...
